Join our community of smart investors

Hutchison China Meditech's drug trial fails

The drug developer has seen one of its cancer trials fail at the final hurdle
November 21, 2018

A final-phase trial of Hutchison China Meditech’s (HCM) cancer drug fruquintinib has failed to demonstrate “a statistically significant increase in overall survival” amongst advanced non-small-cell lung cancer patients in China.

IC TIP: Buy at 4,880p

This marked one of four important drug trials as Chi-Med builds on fruquintinib’s commercial launch (the drug has already been approved to treat advanced colorectal cancer). It’s a big disappointment – evident from the share price drop on the day the news was announced – but chairman Simon To has said he still has long-term faith in the drug.